Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 7, 2006; 12(25): 4038-4043
Published online Jul 7, 2006. doi: 10.3748/wjg.v12.i25.4038
Published online Jul 7, 2006. doi: 10.3748/wjg.v12.i25.4038
Treatment group | Serum HBV DNA (copies/mL) | ||||
0 wk | 4 wk | 8 wk | 12 wk | 16 wk | |
Group 1 normal diet recipients (n = 9) | 1.35E05 ± 3.64E04 | 1.34 E05 ± 3.20 E04 | 1.53 E05 ± 3.10 E04 | 1.30 E05 ± 2.43 E04 | 2.59 E05 ± 9.37 E04 |
Group 2 lamivudine recipients (n = 9) | 1.20 E05 ± 2.54 E04 | 5.52 E04 ± 1.63 E04b | 2.48 E04 ± 8.12E03b,d | 1.34 E04 ± 4.48 E03b,d | 1.12 E05 ± 2.70 E04 |
Group 3 Sp recipients (n = 9) | 1.73 E05 ± 4.69 E04 | 8.39 E04 ± 4.32 E04 | 4.07 E04 ± 1.63 E04a,d | 1.19 E04 ± 7.53 E03b,d | 1.91 E05 ± 6.87 E04 |
-
Citation: Wang R, Du ZL, Duan WJ, Zhang X, Zeng FL, Wan XX. Antiviral treatment of hepatitis B virus-transgenic mice by a marine organism,
Styela plicata . World J Gastroenterol 2006; 12(25): 4038-4043 - URL: https://www.wjgnet.com/1007-9327/full/v12/i25/4038.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i25.4038